Literature DB >> 15138174

Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins.

Hideyuki Arimitsu1, Jae-Chul Lee, Yoshihiko Sakaguchi, Yuji Hayakawa, Michiko Hayashi, Miki Nakaura, Hikaru Takai, Song-Nan Lin, Masafumi Mukamoto, Tom Murphy, Keiji Oguma.   

Abstract

Mice and ducks were subcutaneously immunized with recombinant whole heavy (H) chains of Clostridium botulinum type C and D neurotoxins, which were expressed as glutathione S-transferase fusion proteins. In the case of mice, it was confirmed that two immunizations with type C- and D-H chains, 10 microg each time, significantly increased the specific antibodies against 100-kDa H chains of type C and D neurotoxins in an immunoblot analysis and an enzyme-linked immunosorbent assay, respectively. The mice immunized with type C- and D-H chains showed no symptoms of botulism when they were challenged with C- and D-16 S toxins at doses, given intraperitoneally, of up to 10(5) and 10(6) minmum lethal doses (MLD), respectively, per mouse. Ducks were immunized with a total of 100 microg of type C-H chain. The ducks also developed specific antibodies to the type C-H chain and showed significant protection against a challenge with 10(3) duck MLD of C-16 S toxin given intravenously. These results indicate that recombinant whole H chains can be used as an effective and safe vaccine for type C and D botulism in domestic animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138174      PMCID: PMC404583          DOI: 10.1128/CDLI.11.3.496-502.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  14 in total

1.  Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin.

Authors:  J L Holley; M Elmore; M Mauchline; N Minton; R W Titball
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles.

Authors:  C C Shone; P Hambleton; J Melling
Journal:  Eur J Biochem       Date:  1987-08-17

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Microsequencing of proteins electrotransferred onto immobilizing matrices from polyacrylamide gel electrophoresis: application to an insoluble protein.

Authors:  H Hirano; T Watanabe
Journal:  Electrophoresis       Date:  1990-07       Impact factor: 3.535

Review 5.  Structure and function of Clostridium botulinum toxins.

Authors:  K Oguma; Y Fujinaga; K Inoue
Journal:  Microbiol Immunol       Date:  1995       Impact factor: 1.955

6.  Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains.

Authors:  K Oguma; B Syuto; H Iida; S Kubo
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

7.  Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice.

Authors:  L A Woodward; H Arimitsu; R Hirst; K Oguma
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

8.  Molecular composition of the 16S toxin produced by a Clostridium botulinum type D strain, 1873.

Authors:  H Nakajima; K Inoue; T Ikeda; Y Fujinaga; H Sunagawa; K Takeshi; T Ohyama; T Watanabe; K Inoue; K Oguma
Journal:  Microbiol Immunol       Date:  1998       Impact factor: 1.955

9.  Homogeneity and heterogeneity of toxins produced by Clostridium botulinum type C and D strains.

Authors:  K Oguma; B Syuto; T Agui; H Iida; S Kubo
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

10.  Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.

Authors:  M A Clayton; J M Clayton; D R Brown; J L Middlebrook
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more
  6 in total

1.  High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.

Authors:  Ebrahim Valipour; Mir-Latif Moosavi; Jafar Amani; Shahram Nazarian
Journal:  World J Microbiol Biotechnol       Date:  2014-01-29       Impact factor: 3.312

2.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

Review 3.  Major pathogenic Clostridia in human and progress toward the clostridial vaccines.

Authors:  Lida Abdolmohammadi Khiav; Azadeh Zahmatkesh
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

4.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

5.  Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle.

Authors:  Clóvis Moreira; Marcos R A Ferreira; Carlos E P da Cunha; Rafael A Donassolo; Paula F Finger; Gustavo M S G Moreira; Denis Y Otaka; Loise A de Sousa; José D Barbosa; Ângela N Moreira; Felipe M Salvarani; Fabricio R Conceição
Journal:  Toxins (Basel)       Date:  2018-09-20       Impact factor: 4.546

6.  An adenoviral vector-based mucosal vaccine is effective in protection against botulism.

Authors:  Q Xu; M E Pichichero; L L Simpson; Md Elias; L A Smith; M Zeng
Journal:  Gene Ther       Date:  2009-01-08       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.